Your web browser is outdated and may be insecure

The RCN recommends using an updated browser such as Microsoft Edge or Google Chrome

Pregnancy prep in the age of vapes and weight‑loss jabs

Dr Wendy Norton 16 Nov 2026

November’s National Fertility Awareness Week is a key moment for nurses to offer preconception advice, to address current health issues and modifiable risk factors. With vaping and use of weight-loss jabs on the rise, patients need clear guidance to manage safe, informed pregnancy planning.

Infertility affects around one in every six to seven couples in the UK, and demand for assisted conception continues to rise. IVF treatment numbers have almost tripled over the past 30 years, increasing from roughly 19,000 cycles in the early 1990s to 53,000 in 2024. As more people seek support, NHS funded IVF eligibility criteria have been set for managing limited resources and prioritising those with the highest chance of success.Although policies vary across the UK, several criteria remain consistent.

Most regions require both partners to be non smokers and set a female BMI range of 19–30, with some areas tightening the upper limit to 25. Maternal age restrictions (notably under 40, with limited access up to 42) add further time pressures for patients trying to meet these requirements.These rules can create difficult dilemmas. To qualify for funded treatment, some patients switch from smoking to vaping or consider GLP 1 weight loss medications. While both may seem like helpful solutions, they introduce new reproductive risks that need careful guidance.

Smoking, vaping and fertility

Smoking significantly reduces fertility in both men and women, doubling the rate of infertility compared to non smokers. In women, smoking can damage egg DNA and contribute to earlier menopause. In men, cigarette toxins may increase sperm DNA fragmentation, which is associated with miscarriage.

Many smokers turn to vaping as a cessation tool. Evidence shows nicotine e cigarettes can improve quit rates by around 60% compared to traditional nicotine replacement therapy. However, vaping still introduces nicotine, heavy metals, and harmful chemical toxins into the body, posing reproductive risks.

Research shows women who vape may have lower Anti Müllerian Hormone levels, a key indicator used to estimate their ovarian reserve. Vaping has also been linked to poorer egg quality, irregular ovulation and disrupted menstrual cycles. Chemicals in e liquids may cause inflammation of the uterine lining, reducing the chance of implantation, disrupting early placental development, and increasing risks of preterm birth and low birth weight. For men, vaping and e-cigarette use has been associated with lower sperm counts, altered morphology and reduced motility.

Oxidative stress caused by vaping may also damage sperm DNA.NHS fertility policies treat vaping and smoking similarly; often requiring complete cessation of tobacco and nicotine, including e cigarettes, of both partners before approving IVF funding.

Patients should be advised that vaping is not a safe preconception alternative and that it takes around three months after stopping for the body to clear residual toxins and for reproductive health to recover. Nurses can support patients with licensed Nicotine Replacement Therapy (NRT) products like patches or gum, which have strong safety data for pregnancy.

Weight, GLP 1 agonists and fertility

Excess body weight can affect fertility for those trying to conceive naturally or through assisted conception. High insulin levels associated with higher BMI can disrupt ovulation, contribute to irregular periods, and are closely linked to Polyendocrine Metabolic Ovarian Syndrome (PMOS). A high BMI can also reduce IVF success rates, require higher doses of stimulating medications, which amplifies the risk of ovarian hyperstimulation syndrome. and increase pregnancy complications such as gestational diabetes and preeclampsia.

GLP 1 receptor agonists are approved in the UK for type 2 diabetes and chronic weight management. Their use has grown rapidly, with an estimated 8.3 million people in the UK having used or considered them. Clinical data reports a substantial 15% to 25% reduction in total body weight at the one-year mark, often far beyond what lifestyle changes alone achieve.Because weight loss can improve ovulation and enhance fertility treatment outcomes, GLP 1 medications may appear to be an ideal solution.

However, they are strictly contraindicated while trying to conceive, during pregnancy, or while breastfeeding due to limited safety data and potential risks to the developing foetus. These medications have long half lives, remaining active for weeks after the final dose.

The MHRA recommends a “washout period” of at least two months for Wegovy® and Ozempic®, and at least one month for Mounjaro®, before trying to conceive. GLP 1 medications can also affect oral contraceptive absorption due to gastrointestinal side effects. The MHRA advises using condoms for four weeks after starting treatment and after each dose increase or switching to a non oral contraceptive method during treatment and the washout period.

Vaping and GLP 1 injection use must be discontinued well before trying to conceive to free the body of substances that may affect fertility or early foetal development. This window creates valuable opportunities for personalised support to improve their chances of a healthy pregnancy.

Dr Wendy Norton

Women's Health Forum

Honorary Senior Research Fellow, Faculty of Health and Life Sciences at De Montfort University, Leicester.

Honorary Senior Research Fellow, Faculty of Health and Life Sciences at De Montfort University, Leicester.

Associate Professor in the School of Nursing and Midwifery at De Montfort University for eighteen years, leading women’s health and sexual health modules, until her retirement four years ago. Wendy gained her PhD in Sociology and Nursing in 2018 and is presently involved in endometriosis, menopause, and assisted reproduction research.

Page last updated - 16/11/2026